Compare AbCellera Biologics Inc (ABCL) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs General Motors Company — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while General Motors Company trades at $75.72 (market cap $68.55B). The key difference: General Motors Company is far larger — about 29.2× AbCellera Biologics Inc's market cap, and General Motors Company pays a 0.95% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GM | |
|---|---|---|
Market Cap | $2.35B | $68.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $86.38 |
52-Week Low | $2.78 | $48.89 |
Enterprise Value | $1.99B | $171.89B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
General Motors (GM) trades at $76.03, showing minimal daily movement with a 0.04% gain. The stock presents a mixed technical picture with bearish moving averages but oversold RSI conditions. Fundamentally, GM demonstrates strong cash flow generation ($26.9B operating cash flow in 2025) and consistent earnings beats, though profit margins remain thin at 1.38%. Recent news highlights strategic partnerships with Micron Technology and ongoing EV transition challenges.
GM offers value with attractive valuation multiples (P/S: 0.4x, P/B: 1.12x) and analyst consensus pointing to 31% upside potential. However, investors face risks from cyclical auto demand, margin pressure, and high debt levels. The company's scale and cash flow strength provide stability, but execution on EV strategy remains critical for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
